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Fluoroquinolones came into widespread use in African countries in the early 2000s,
after patents for the first generation of these drugs expired. By that time, quinolone
antibacterial agents had been used intensively worldwide and resistant lineages of many
bacterial species had evolved. We sought to understand which Gram negative enteric
pandemic lineages have been reported fromAfrica, as well as the nature and transmission
of any indigenous resistant clones. A systematic review of articles indexed in the
Medline and AJOL literature databases was conducted. We report on the findings of 43
eligible studies documenting local or pandemic fluoroquinolone-resistant enteric clones
in sub-Sahara African countries. Most reports are of invasive non-typhoidal Salmonella
and Escherichia coli lineages and there have been three reports of cholera outbreaks
caused by fluoroquinolone-resistant Vibrio choleraeO1. Fluoroquinolone-resistant clones
have also been reported from commensals and animal isolates but there are few
data for non-Enterobacteriaceae and almost none for difficult-to-culture Campylobacter
spp. Fluoroquinolone-resistant lineages identified in African countries were universally
resistant to multiple other classes of antibacterial agents. Although as many as 972
non-duplicate articles refer to fluoroquinolone resistance in enteric bacteria from Africa,
most do not report on subtypes and therefore information on the epidemiology
of fluoroquinolone-resistant clones is available from only a handful of countries in
the subcontinent. When resistance is reported, resistance mechanisms and lineage
information is rarely investigated. Insufficient attention has been given to molecular and
sequence-basedmethods necessary for identifying and tracking resistant clones in Africa
and more research is needed in this area.
Keywords: fluoroquinolone resistance, quinolone resistance, antimicrobial resistance, Africa, Escherichia coli,
Salmonella, Vibrio cholerae, Campylobacter
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INTRODUCTION
Recent Trends in Fluoroquinolone Use and
Resistance in Africa
The antibacterial activity of nalidixic acid, a derived by-
product from the synthesis of the antimicrobial chloroquine,
was discovered in the 1960s. This first quinolone was
the base molecule used to synthesize the even more
active fluoroquinolones, which also had more favorable
pharmacokinetics (Mitscher, 2005). First generation
fluoroquinolones (second generation quinolones), like
ciprofloxacin, became clinically available in the 1980s and were
patent protected until the 2000s (Paton and Reeves, 1988). Until
recently, ciprofloxacin was the most potent fluoroquinolone and
highly active against virtually all bacterial enteropathogens. It
was therefore widely considered to be the drug of choice for
patients with enteric fever, severe gastroenteritis, cholera and
salmonellosis (Brown and Reeves, 1997). These and other enteric
infections are common in the sub-Saharan African sub-continent
where an estimated 960–980 million people, most of them young,
share the highest risk of infectious disease. Within a year of
introduction of ciprofloxacin, resistance appeared and soon
became commonplace (Brown and Reeves, 1997). However,
30 years since its introduction, ciprofloxacin is still the most
commonly prescribed fluoroquinolone along with levofloxacin,
ofloxacin, and moxifloxacin (Redgrave et al., 2014).
Being orally active, broad-spectrum, and heat-stable, the
potential for fluoroquinolone application as well as misuse was
high. When the efficacy of earlier orally active antibacterials
such as the tetracyclines, amino penicillins, and trimethoprim-
sulphonamide combinations declined due to rapidly rising
antimicrobial resistance rates, fluoroquinolones were recognized
as effective alternatives for common and life-threatening
infections (Green and Tillotson, 1997). They quickly became
among the most widely applied antimicrobials worldwide. The
initial high cost of these drugs prohibited their use in the
least aﬄuent African settings. The situation changed upon
ciprofloxacin patent expiry in 2003, when cheap generics entered
African markets. Other fluoroquinolones, such as pefloxacin,
met similar fates, and the fluoroquinolones rapidly became first-
line drugs for the empiric treatment of many life-threatening
infections (Orogade and Akuse, 2004).
The WHO recently highlighted fluoroquinolone resistance
in Escherichia coli and related organisms as a principal public
health threat (WHO, 2014). Fluoroquinolone resistance was
rare worldwide in the 1980s. In Nigeria, as elsewhere, rapid
escalation of fluoroquinolone use has been paralleled by a
similarly rapid increase in the prevalence of resistant bacteria,
including enterics (Omigie et al., 2009; Lamikanra et al., 2011;
Namboodiri et al., 2011). In part because quinolone resistance
evolved later but also perhaps because mechanisms conferring
resistance to a wide range of drugs may have predominated
before quinolone-specificmechanisms evolved, fluoroquinolone-
resistant strains are typically resistant to multiple antimicrobials
(Lamikanra et al., 2011; Namboodiri et al., 2011). Other factors
may account for association of fluoroquinolone resistance and
multiple resistance in Africa in particular. Quinolones were
widely used for decades elsewhere in the world so that resistance
genes and resistant clones had already evolved by the time
fluoroquinolones were significantly employed in Africa. It has
been hypothesized that chloroquine contributed to selective
pressure for fluoroquinolone-resistant bacteria in malaria
endemic settings but available data do not support this hypothesis
for Nigeria (Davidson et al., 2008; Lamikanra et al., 2011).
Irrespective of other factors driving fluoroquinolone resistance
in enterics across Africa, introduction of fluoroquinolones into
routine care in African clinics rapidly enhanced their selection
and transmission in a paradigm that is instructive for future
antibacterial introductions. In this paper, we review what is
known about fluoroquinolone resistant enteric clones in Africa.
Fluoroquinolone Resistant Enteric
Organisms and Overview of Clonal
Expansion Problem
Among enteric bacteria, fluoroquinolone resistance has
predominantly been reported in the literature on E. coli
(Robicsek et al., 2006), Enterobacter sp. (Robicsek et al., 2006;
Cattoir et al., 2007), Citrobacter freundii (Cattoir et al., 2007)
Klebsiella pneumoniae (Robicsek et al., 2006), Salmonella
Typhi (Dimitrov et al., 2010; Baker et al., 2013), Salmonella
enterica (Yanagi et al., 2009), Shigella flexneri (Hata et al.,
2005), and Vibrio cholerae (Ismail et al., 2011). There are
multiple mechanisms by which these species acquire resistance
to fluoroquinolones. Resistance was initially recognized to be
due to point mutations in quinolone resistance determining
regions (QRDRs) of the gyrA and parC quinolone target genes
and may also be attributable to other chromosomal genes
that promote quinolone eﬄux. Secondly, plasmid mediated
quinolone resistance (PMQR) can be mediated through QRDR-
protective qnr alleles, the ciprofloxacin-acetylating aac(6)-Ib-cr
allele or quinolone-eﬄux genes qepA and oqxAB (Redgrave et al.,
2014; Blair et al., 2015). In general fluoroquinolone-resistant
strains could have multiple genetic bases for resistance. Some
accumulate multiple QRDR mutations and others carry one
or more PMQR genes with one or more QRDR mutations.
Sequential transition of a strain to higher level resistance is
generally attributable to multiple but independent genetic
events. Selective pressure from widespread fluroquinolone use
appears to have allowed clones that have independently acquired
a combination of natural mutation and recombination events to
expand internationally (Hooper, 2003; Strahilevitz et al., 2009;
Redgrave et al., 2014).
Fluoroquinolone use is an important selector of evolutionary
successful resistant lineages but unlikely to be the only one
(Baker et al., 2013). More research is needed to promote in-depth
understanding of the drivers of emergence and persistence of
resistant lineages. Bacterial clones are, by definition, descended
from a common ancestor. Evolution within clones and horizontal
gene transfer among them subsequently leads to diversification
so that organisms of clonal origin may not always be easily
discernible and clonal expansion could be difficult to distinguish
from evolutionary convergence. Clone descriptions vary and only
a subset of resistance mechanisms receive sufficient focus.
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Examples of well-known clonal lineages include lineages
of E. coli ST131, the fluoroquinolone insensitive and multi-
drug resistant (MDR) Salmonella Typhimurium DT104, and
the ciprofloxacin-resistant S. enterica serotype Kentucky ST198-
X1-SGI1 clone. These clonal groups are marked by rapid and
extensive dissemination and have been extensively tracked in
many parts of the world (Threlfall, 2000; Le et al., 2013; Petty
et al., 2014). However, “worldwide” or “global” studies of these
and other clones frequently under-represent African isolates, and
in some cases omit them altogether, pointing to the need for a
systematic review of published literature on clones in Africa.
The very definition of a “resistant clone” can vary among
studies causing problems in understanding the true scope
of clonal emergence and subsequent expansion. Genetic
studies, preferably sequence-based, are the gold standard for
defining clones. Such studies include phylogenetic studies of
resistant bacteria that have been characterized via multilocus
sequence typing/analysis or whole genome sequencing (WGS)
(Roumagnac et al., 2006; Dahiya et al., 2013; Wong et al.,
2015). Sequence analysis of resistance genes or plasmids in
the context of well-characterized strains can also indicate
clonality but, in the absence of host background sequence,
cannot robustly differentiate genetically distinct clones. Other
studies characterize resistant clones by phenotypic methods
such as serogrouping and resistant profiles or pulse-field gel
electrophoresis (PFGE; Ke et al., 2014), which looks at genetic
profile based on restriction digestion sites. Africa does have an
international network to compare PFGE profiles across countries
(http://www.pulsenetinternational.org/networks/africa/).
However, it is known that PFGE profiles of a single clone may
not be identical or chromosomal rearrangements may produce
significantly different profiles within a clone (Ismail et al.,
2011; Price et al., 2013). Mobile elements can be acquired in
different lineages and identical phenotypic characteristics do not
necessary imply genetic relatedness (Chattaway et al., 2014).
A clone definition is as good as the discovery methodology.
Thus clones are often redefined when more and better
information become available. Phenotypic traits—such as
serogrouping, virulence, or biochemical profiling that can be
acquired convergently in different lineages—cannot be accurately
used to track clonal expansion. This has important implications
for much of the literature from Africa where sequence-
based studies are few. However, the so-called next generation
and indeed third-generation sequencing technologies offer an
affordable solution to sequence-based clone identification that is
increasingly adopted in African studies with great potential for
the future. Our review of global fluoroquinolone resistance and
clonal expansion in Africa included genetic methodologies such
as WGS, detection, or sequencing of fluoroquinolone resistance
genes with well characterized strains as the eligible criteria.
SYSTEMATIC SEARCH METHODS
This systematic review was conducted in accordance with the
preferred reporting items of systematic reviews and meta-
analyses (PRISMA) guidelines (Moher et al., 2009). Relevant
English articles available in the Medline (Pubmed) and African
Journals Online (AJOL) databases were retrieved by two authors
using predefined search terms (Table S1). The literature search
was conducted until October 2015.
Figure 1 summarizes the study selection process. All duplicate
articles were removed. Fluoroquinolone resistant organisms are
defined as those having minimum inhibitory concentrations
above the CLSI breakpoints (2µg/ml for ciprofloxacin) or zone
sizes below the CLSI breakpoints in standardized disk tests.
Strains with MICs above the susceptible breakpoint (0.06µg/ml
and 1µg/ml for ciprofloxacin in Salmonella and other enterics
respectively) are described as fluoroquinolone non-susceptible in
this review. The eligibility of published reports in this review
was based primarily on polymerase chain reaction (PCR) or
sequence-based detection of fluoroquinolone resistance genes
and the use of at least one molecular tool for assessing clonality
of the enteric pathogen including multi-locus sequencing typing
(MLST), multi-locus sequencing analysis (MLSA), clone-specific
PCR, or PFGE, subsequent sequencing of fluoroquinolone
resistance genes, PCR amplicons, and WGS of the enteric
organism. Studies where only phenotypic resistance screening
methods were used were excluded.
RESULTS
Literature Search and Characteristics of
the Studies Included in the Systematic
Review
The systematic search of the two electronic databases yielded
1313 articles (Figure 1). After the removal of duplicate studies
and assessments of titles and abstracts, 776 full-text articles were
screened of which 43 studies were considered eligible for the
qualitative analysis according to our inclusion criteria (three
articles were not included due to inaccessibility). The majority
of the articles retrieved were single center studies. Altogether,
eligible studies were identified from 17 African countries, less
than half of those south of the Sahara. Furthermore, 25 of
these studies—almost two-thirds—were performed in just four
countries: CAR, Kenya, Nigeria, and South Africa.
The search retrieved articles focused on V. cholerae, E. coli,
and other Enterobacteriaceae and Campylobacter spp. but
overall, published work on fluoroquinolone-resistant enteric
clones in Africa is predominantly focused on Salmonella and
whole genome sequence data-based studies are almost entirely
limited to this genus. One possibility is that the identification of
hypervirulent invasive non-typhoidal Salmonella lineages on the
continent (Okoro et al., 2012) is fueling this research. However,
our reading of the literature appears to point to the enhanced
focus on the molecular epidemiology of Salmonella in East
and Southern Africa as being responsible for identifying this
clonal expansion problem in the first place and it is probable
that expanded research on other pathogens will uncover other
local clones.
Many studies seeking fluoroquinolone-resistant strains found
strains with intermediate susceptibility and/or strains that were
resistant to the quinolones but not the fluoroquinolones (Table
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FIGURE 1 | Summary of study selection process.
S2). As resistance to the fluoroquinolones typically evolves in
a stepwise fashion, the wide prevalence of these intermediate
strains is worrisome. While there are very few studies reporting
fluoroquinolone-resistant E. coli clones, reports are increasingly
using sequence-based methods to identify clones, specifically,
MLST. The predominance of MLST has been helpful in placing
the findings from African countries into global context and
demonstrates the extension of knowledge that can come from
using sequence-based tools in small studies (Tables 2, 3). There
are two E. coli MLST schemes in the literature and whilst the
Lacher et al. scheme (Lacher et al., 2007) has been used in African
studies (Feglo et al., 2013), the more widely used (Wirth et al.,
2006) scheme is more frequently applied, making comparisons
among these many small studies possible. Where MLST was not
applied per se, PCRmarkers for MLST-defined ST131 clades were
used to identify members of those clones (Peirano et al., 2011,
2014; Albrechtova et al., 2012; Gqunta and Govender, 2015).
Methodology of this type could be developed for and applied
to other clones that are later found to be of interest in Africa
(Doumith et al., 2015). A few African studies, generally older
ones, have used PCR-based techniques and PFGE (Lavollay et al.,
2006; Kariuki et al., 2007; Peirano et al., 2011). While these
studies are the principal sources of information on distribution
of FQREC soon after these strains evolved in Africa, it is difficult
to connect the clones identified therein to those reported more
recently.
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Data from Salmonella are predominantly available from
Eastern and Southern Africa, and there are two multicountry
studies focused on Salmonella Kentucky ST198 (Le et al., 2011,
2013). V. cholerae studies reported from outbreaks in Western
(Nigeria, Cameroon), Eastern (Kenya), and Southern Africa
with one pair of studies focused on the same outbreak on
either side of the Nigeria-Cameroon border (Quilici et al., 2010;
Marin et al., 2013). Most E. coli data studied in this review
came from single country studies, limited to CAR (Janatova
et al., 2014), Ghana (Namboodiri et al., 2011; Feglo et al., 2013)
Kenya (Kariuki et al., 2007; Albrechtova et al., 2012), Nigeria
(Lamikanra et al., 2011; Aibinu et al., 2012a), and South Africa
(Gqunta and Govender, 2015). Intercontinental studies generally
included isolates from only one sub-Saharan African country
(CAR or South Africa) and other non-African countries (Lavollay
et al., 2006; Peirano et al., 2011, 2014). Therefore there are no
data comparing FQREC isolates from different countries in sub-
SaharanAfrica. Additionally, multicountry or “global” studies are
typically including only one country from within sub-Saharan
Africa, even though it is well known that biological diversity
on the African continent exceeds that in most other parts of
the world.
Vibrio cholerae
Cholera, the pandemic diarrheal disease caused by toxigenic
V. cholerae strains, has become increasingly problematic across
Africa in the last two decades but fluoroquinolone resistance has
only been recently studied (Scrascia et al., 2006, 2009; Mintz and
Guerrant, 2009), Quilici et al. (2010) described the microbiology
of a cholera outbreak that spanned the borders of Nigeria and
Cameroon in 2009 and (Quilici et al., 2010) was due to a single
V. choleraeO1Ogawa El-tor clone. The ctxBDNA sequence from
this clone was similar (only 3 SNPs) to a strain identified in India
in 2007 but different from variants isolated in southern Africa,
indicating a possible transmission from Asia to Africa. This
clone was resistant to nalidixic acid and MICs to ciprofloxacin
were 0.25–0.5µg/ml, placing them in the susceptible category
(based on general enterobacterial breakpoints), although these
MICs approach the reduced susceptibility breakpoint of 1µg/ml.
Strains belonging to this clone contained mutations in the QRDR
of gyrA (Ser83-Ile) and parC (Ser85-Leu) but no mutations in
gyrB or parE. A more comprehensive Nigeria study looking at
V. cholerae O1 strains isolated in the early 1970’s and comparing
themwith strains ofV. choleraeO1 and non-O139 strains isolated
in 2009–2010 indicated that gyrA (Ser83-Ile) and parC (Ser85-
Leu) mutations were not present in the 1970’s or in non-O1
clinical isolates (Marin et al., 2013). Interestingly, MLVA analysis
clustered the 1970’s O1 El-tor strain strains with epidemic O1
El-tor strains but the strains had different ctxB types and vibrio
17th pandemic island (VSP-II) profiles indicating that they do not
represent one clone (Marin et al., 2013). This can be explained
by the housekeeping genes used in this analysis (pyrH, recA, and
mdh) being highly conserved in V. cholerae serogroup strains.
Approaches using whole genome sequence may be required to
further define the inter-relatedness of these O1 strains.
The most in-depth assessment of fluoroquinolone resistant
mechanisms was a South African study focused on a V. cholerae
O1 Ogawa El-tor clone outbreak (Ismail et al., 2011). A selection
of strains was assessed for the presence of plasmid-mediated
quinolone resistance (PMQR) genes (qnrA, qnrB, qnrS, qnrC,
and qepA) as well as Vibrio quinolone resistance determinant
(qnrVC3). Nalidixic acid resistance was investigated in the
presence and absence of two eﬄux pump inhibitors and QRDR
mutations were identified by sequencing. The South Africa
strains were negative for any PMQR genes and there was
no evidence of active eﬄux conferring quinolone resistance.
Nalidixic acid resistance was attributable to gyrA (Ser83-Ile)
and parC (Ser85-Leu) mutations (Ismail et al., 2011). All of the
recent outbreak strains described in these three studies were
V. cholerae O1 El-tor (two studies also indicated serogroup
Ogawa) which showed resistance to nalidixic acid but only a
reduced susceptibility to ciprofloxacin (Table 1). It is highly likely
that these strains are the same clone and that the same QRDR
mutations are responsible for fluoroquinolone resistance. High
levels of resistance to nalidixic acid or reduced susceptibility
to ciprofloxacin in likely similar V. cholerae O1 clones causing
epidemics in DRC and Kenya have also been shown (Mercy
et al., 2014; Miwanda et al., 2015; Table 1), but a lack of standard
methodology for clonal analysis prevents an understanding of
clonal spread across Africa. Although ciprofloxacin has only a
reduced susceptibility in these strains and continues to be used
for cholera management, if additional mutations occur in these
circulating clones, resistance to ciprofloxacin may develop.
Campylobacter
Campylobacter jejuni is a leading enteric bacterial pathogen in
developing countries particularly among children below the age
of 5 years. In spite of numerous reports of C. jejuni as well as
its resistance to fluoroquinolones (Coker et al., 2002) data on
clones of the organisms causing human infections in Africa are
non-existent. Characterization of 46 isolates from chickens in
Senegal by MLST revealed seven clonal complexes which have
all been associated with human disease elsewhere (Kinana et al.,
2006). Clonal complex 353 was the most common and Thr-86-
Ile substitution in gyrA was the major mechanism of quinolone
resistance. Rather than diffusion of a single or a few clones,
acquisition of resistance appears to be occurring in different
lineages in response to selective pressure. Similarly, another
study from Senegal, strain typing of 99 chicken and 10 human
isolates of C. jejuni by PFGE that uncovered common patterns
among strains circulating in human and poultry, though were
no particular predominant pulsotypes (Cardinale et al., 2006).
Altogether, although the data are few, there is yet to be robust
evidence for expanded fluoroquinolone resistant Campylobacter
clones.
Enteric and Commensal Escherichia coli
and Shigella
Diarrhea was the third leading cause of death in children
under five in sub-Saharan Africa in 2013 (after malaria and
pneumonia), accounting for 12% of the estimated 3.6 million
deaths (Liu et al., 2015). In sub-Saharan Africa and south Asia,
most attributable cases of moderate-to-severe childhood diarrhea
in under-fives are due to the enteric bacteria E. coli and Shigella
Frontiers in Microbiology | www.frontiersin.org 5 April 2016 | Volume 7 | Article 558
Chattaway et al. Fluoroquinolone-Resistant Enterics in Africa
T
A
B
L
E
1
|
C
h
a
ra
c
te
ri
z
a
ti
o
n
o
f
e
li
g
ib
le
a
rt
ic
le
s
th
a
t
s
o
u
g
h
t
fl
u
o
ro
q
u
in
o
lo
n
e
re
s
is
ta
n
t
c
lo
n
e
s
in
h
u
m
a
n
s
a
n
d
a
n
im
a
ls
**
.
C
o
u
n
tr
y
O
rg
a
n
is
m
N
o
.
re
s
is
ta
n
t*
*/
N
o
to
ta
l
ID
m
e
th
o
d
S
tu
d
y
p
e
ri
o
d
S
tu
d
y
p
o
p
u
la
ti
o
n
G
e
n
o
ty
p
in
g
to
o
ls
R
e
s
is
ta
n
c
e
te
s
ti
n
g
R
e
fe
re
n
c
e
s
W
G
S
M
L
S
T
E
R
IC
-P
C
R
P
F
G
E
R
e
p
P
C
R
O
th
e
r*
P
M
Q
R
Q
R
D
R
E
ffl
u
x
p
u
m
p
u
p
-
re
g
u
la
ti
o
n
a
a
c
(6
′
)-
Ib
-c
r
A
n
g
o
la
E
.
c
o
li
9
/1
9
B
,
S
2
0
0
9
S
tr
a
y
d
o
g
s
–
–
–
√
–
–
√
–
–
–
A
lb
re
c
h
to
va
e
t
a
l.,
2
0
1
4
a
C
a
m
e
ro
o
n
V
.
c
h
o
le
ra
e
O
1
O
g
a
w
a
E
l-
to
r
0
/9
B
,
S
,
M
2
0
0
9
O
u
tb
re
a
k
–
–
–
–
–
–
–
√
–
–
Q
u
ili
c
ie
t
a
l.,
2
0
1
0
C
e
n
tr
a
l
A
fr
ic
a
n
R
e
p
u
b
lic
E
n
te
ro
b
a
c
te
ri
a
c
e
a
e
3
3
/1
2
1
B
,
S
2
0
1
1
H
u
m
a
n
/w
ild
lif
e
–
–
–
√
–
√
–
–
J
a
n
a
to
va
e
t
a
l.,
2
0
1
4
E
n
te
ro
b
a
c
te
ri
a
c
e
a
e
6
5
/6
5
B
2
0
1
1
–
2
0
1
2
C
lin
ic
a
li
so
la
te
s
(s
u
rg
ic
a
ls
ite
in
fe
c
tio
n
s)
–
√
√
–
√
–
√
–
–
√
R
a
fa
ie
t
a
l.,
2
0
1
5
E
.
c
o
li
1
0
/1
2
1
B
,
M
2
0
1
1
G
o
ri
lla
s
a
n
d
o
th
e
r
w
ild
lif
e
–
√
–
–
–
–
√
–
–
√
J
a
n
a
to
va
e
t
a
l.,
2
0
1
4
E
.
c
o
li
1
0
/1
0
B
,
M
2
0
0
0
–
2
0
0
4
H
o
sp
ita
lc
lin
ic
a
l
is
o
la
te
s
–
–
–
√
√
–
–
–
–
√
L
a
vo
lla
y
e
t
a
l.,
2
0
0
6
S
.
Ty
p
h
i
0
/1
9
B
,
S
1
9
1
6
–
2
0
0
4
V
a
ri
o
u
s
√
–
–
–
–
–
–
–
–
–
H
o
lt
e
t
a
l.,
2
0
0
8
C
o
te
d
’I
vo
ire
E
.
c
o
li,
E
n
te
ro
b
a
c
te
ri
c
e
a
e
4
4
/1
0
1
B
,
S
2
0
1
2
H
u
m
a
n
,
d
o
g
,
w
ild
lif
e
–
–
–
√
–
–
√
–
–
√
A
lb
re
c
h
to
va
e
t
a
l.,
2
0
1
4
b
D
R
C
S
a
lm
o
n
e
lla
(N
T
S
)
0
/2
3
3
B
,
S
2
0
0
7
–
2
0
1
1
C
o
m
m
u
n
ity
a
n
d
C
lin
ic
a
li
so
la
te
s
–
–
–
√
–
–
√
√
–
–
L
u
n
g
u
ya
e
t
a
l.,
2
0
1
3
V
.
c
h
o
le
ra
e
0
/1
0
9
3
B
,
S
1
9
9
7
–
2
0
1
2
C
lin
ic
a
lI
so
la
te
s
√
–
–
–
–
M
LV
A
–
–
–
–
M
iw
a
n
d
a
e
t
a
l.,
2
0
1
5
G
h
a
n
a
E
.
c
o
li
2
3
/2
9
3
B
,
M
2
0
0
6
–
2
0
0
8
C
lin
ic
a
li
so
la
te
s
fr
o
m
te
rt
ia
ry
c
a
re
h
o
sp
ita
ls
–
√
–
–
–
–
√
√
–
–
N
a
m
b
o
o
d
ir
ie
t
a
l.,
2
0
1
1
E
.
c
o
li
2
8
/2
9
B
,
M
2
0
0
8
–
2
0
0
9
C
lin
ic
a
li
so
la
te
s:
B
lo
o
d
,
u
ri
n
e
,
sp
u
tu
m
a
n
d
w
o
u
n
d
–
√
–
–
–
–
–
–
–
–
F
e
g
lo
e
t
a
l.,
2
0
1
3
E
th
io
p
ia
S
a
lm
o
n
e
lla
1
9
/9
8
B
,
S
2
0
0
0
–
2
0
0
5
A
n
im
a
l/
A
n
im
a
l
p
ro
d
u
c
ts
–
–
–
√
–
–
–
–
–
–
M
o
lla
e
t
a
l.,
2
0
0
7
K
e
n
ya
E
.
c
o
li
6
6
/2
8
9
B
,
M
2
0
0
9
D
o
g
s
(m
a
in
ly
),
c
a
ts
a
n
d
h
u
m
a
n
s
–
–
–
√
–
–
√
–
–
√
A
lb
re
c
h
to
va
e
t
a
l.,
2
0
1
2
E
.
c
o
li
1
2
/1
7
B
,
M
2
0
0
4
–
2
0
0
5
C
lin
ic
a
li
so
la
te
s:
U
ri
n
e
–
–
–
√
–
–
√
–
–
√
K
a
ri
u
k
ie
t
a
l.,
2
0
0
7
V
.
c
h
o
le
ra
e
1
/7
6
B
,
S
2
0
0
7
–
2
0
1
0
C
lin
ic
a
lI
so
la
te
s
–
–
–
√
–
R
ib
o
-t
yp
in
g
–
–
–
–
M
e
rc
y
e
t
a
l.,
2
0
1
4
S
.
K
e
n
tu
c
ky
3
/3
B
,
S
2
0
0
0
–
2
0
0
5
C
lin
ic
a
lI
so
la
te
s
–
–
–
√
–
√
√
–
–
W
e
ill
e
t
a
l.,
2
0
0
6
S
.
Ty
p
h
i
0
/9
4
B
,
S
1
9
8
8
–
2
0
0
8
C
lin
ic
a
li
so
la
te
s
√
–
–
–
–
–
–
–
–
–
K
a
ri
u
k
ie
t
a
l.,
2
0
1
0
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 6 April 2016 | Volume 7 | Article 558
Chattaway et al. Fluoroquinolone-Resistant Enterics in Africa
T
A
B
L
E
1
|
C
o
n
ti
n
u
e
d
C
o
u
n
tr
y
O
rg
a
n
is
m
N
o
.
re
s
is
ta
n
t*
*/
N
o
to
ta
l
ID
m
e
th
o
d
S
tu
d
y
p
e
ri
o
d
S
tu
d
y
p
o
p
u
la
ti
o
n
G
e
n
o
ty
p
in
g
to
o
ls
R
e
s
is
ta
n
c
e
te
s
ti
n
g
R
e
fe
re
n
c
e
s
W
G
S
M
L
S
T
E
R
IC
-P
C
R
P
F
G
E
R
e
p
P
C
R
O
th
e
r*
P
M
Q
R
Q
R
D
R
E
ffl
u
x
p
u
m
p
u
p
-
re
g
u
la
ti
o
n
a
a
c
(6
′
)-
Ib
-c
r
S
.
Ty
p
h
i
0
/1
0
2
B
,
S
2
0
0
1
–
2
0
0
2
C
lin
ic
a
li
so
la
te
s
–
–
–
√
–
–
–
√
–
–
K
a
ri
u
k
ie
t
a
l.,
2
0
0
4
S
.
Ty
p
h
i
N
S
/5
5
N
S
2
0
0
1
–
2
0
0
9
C
lin
ic
a
li
so
la
te
s
√
–
–
–
–
–
–
–
–
–
W
o
n
g
e
t
a
l.,
2
0
1
5
M
a
la
w
i
S
.
Ty
p
h
i
0
/1
1
2
B
,
B
C
1
9
9
8
–
2
0
1
3
C
lin
ic
a
li
so
la
te
s
(b
lo
o
d
)
√
√
–
–
–
–
–
–
–
–
F
e
a
se
y
e
t
a
l.,
2
0
1
5
S
.
Ty
p
h
i
N
S
/1
1
2
N
S
2
0
0
4
–
2
0
1
3
C
lin
ic
a
li
so
la
te
s
√
–
–
–
–
–
–
–
–
–
W
o
n
g
e
t
a
l.,
2
0
1
5
N
ig
e
ri
a
E
.
c
o
li
6
/1
6
2
B
,
S
2
0
0
6
P
o
u
ltr
y/
P
ig
s
–
–
√
–
–
–
√
–
–
√
F
o
rt
in
ie
t
a
l.,
2
0
1
1
E
.
c
o
li
5
7
/1
1
4
B
,
M
2
0
1
0
–
2
0
1
1
H
u
m
a
n
c
lin
ic
a
l
is
o
la
te
s,
b
o
vi
n
e
is
o
la
te
s
fr
o
m
fa
rm
s
–
√
–
–
√
–
√
–
–
√
In
w
e
ze
ru
a
e
t
a
l.,
2
0
1
4
E
.
c
o
li
2
6
/3
2
B
,
M
2
0
1
1
H
u
m
a
n
s
(p
re
g
n
a
n
t
w
o
m
e
n
)
–
√
√
–
–
–
√
–
–
√
F
o
rt
in
ie
t
a
l.,
2
0
1
5
E
.
c
o
li
9
/1
0
9
B
,
M
2
0
0
8
–
2
0
0
9
C
lin
ic
a
li
so
la
te
s
fr
o
m
te
rt
ia
ry
c
a
re
h
o
sp
ita
ls
–
S
T
1
3
1
a
n
d
S
T
1
0
√
–
–
–
√
–
–
√
A
ib
in
u
e
t
a
l.,
2
0
1
2
a
E
.
c
o
li
2
1
/1
2
1
B
,
M
2
0
0
5
H
e
a
lth
y
vo
lu
n
te
e
rs
–
√
–
–
–
fli
C
-R
F
L
P
–
√
√
–
L
a
m
ik
a
n
ra
e
t
a
l.,
2
0
1
1
S
a
lm
o
n
e
lla
(N
T
S
)
1
1
/1
4
9
B
,
S
2
0
0
9
–
2
0
1
1
H
u
m
a
n
/p
o
u
tr
y/
c
a
tt
le
/
fis
h
/v
e
g
e
ta
b
le
–
–
–
–
–
–
√
–
–
–
R
a
u
fu
e
t
a
l.,
2
0
1
3
S
a
lm
o
n
e
lla
(N
T
S
)
2
/2
2
9
B
,
S
2
0
1
0
–
2
0
1
1
P
ig
s
–
–
–
–
–
–
√
–
–
–
F
a
sh
a
e
a
n
d
H
e
n
d
ri
k
se
n
,
2
0
1
4
S
.
H
id
u
d
d
ify
2
4
/1
3
0
B
,
S
2
0
0
1
C
h
ic
k
e
n
s/
p
o
u
ltr
y
m
e
a
t
–
–
–
√
–
–
–
–
–
–
R
a
u
fu
e
t
a
l.,
2
0
0
9
S
.
K
e
n
tu
c
k
y
1
9
7
/1
9
7
B
,
S
1
9
5
9
–
2
0
0
8
H
u
m
a
n
/P
o
u
ltr
y/
se
a
fo
o
d
/r
iv
e
r/
e
n
vi
ro
n
m
e
n
t
–
√
–
√
–
–
√
√
–
√
L
e
e
t
a
l.,
2
0
1
1
S
.
K
e
n
tu
c
k
y
5
5
/5
5
B
,
S
2
0
0
7
–
2
0
1
1
P
o
u
ltr
y/
p
o
u
ltr
y
so
u
rc
e
s
–
–
–
√
–
–
–
–
–
–
R
a
u
fu
e
t
a
l.,
2
0
1
4
S
.
K
e
n
tu
c
k
y
5
4
/7
0
B
,
S
1
9
3
7
–
2
0
1
3
H
u
m
a
n
s/
a
n
im
a
ls
/e
n
vi
ro
n
m
e
n
t
–
√
–
√
–
–
√
√
–
√
L
e
e
t
a
l.,
2
0
1
3
V
.
c
h
o
le
ra
e
O
1
a
n
d
n
o
n
O
1
0
/2
0
B
,
S
,
M
1
9
7
1
–
2
0
1
0
O
u
tb
re
a
k
,
h
is
to
ri
c
a
l,
e
n
vi
ro
n
m
e
n
ta
l
–
–
–
√
–
M
L
S
A
–
√
–
–
M
a
ri
n
e
t
a
l.,
2
0
1
3
V
.
c
h
o
le
ra
e
O
1
O
g
a
w
a
E
l-
to
r
0
/1
0
B
,
S
,
M
2
0
0
9
O
u
tb
re
a
k
–
–
–
–
–
–
–
√
–
–
Q
u
ili
c
ie
t
a
l.,
2
0
1
0
E
.
c
o
li
N
S
/1
2
B
,
M
2
0
0
0
–
2
0
1
0
C
lin
ic
a
li
so
la
te
s
–
√
–
√
–
L
in
e
a
g
e
P
C
R
–
√
–
√
P
e
ir
a
n
o
e
t
a
l.,
2
0
1
4
E
.
c
o
li
0
/2
2
B
,
M
2
0
0
8
–
2
0
0
9
C
lin
ic
a
li
so
la
te
s
(U
ri
n
e
a
n
d
p
u
s)
–
–
–
√
–
–
√
–
–
√
P
e
ir
a
n
o
e
t
a
l.,
2
0
1
1
(C
o
n
ti
n
u
e
d
)
Frontiers in Microbiology | www.frontiersin.org 7 April 2016 | Volume 7 | Article 558
Chattaway et al. Fluoroquinolone-Resistant Enterics in Africa
T
A
B
L
E
1
|
C
o
n
ti
n
u
e
d
C
o
u
n
tr
y
O
rg
a
n
is
m
N
o
.
re
s
is
ta
n
t*
*/
N
o
to
ta
l
ID
m
e
th
o
d
S
tu
d
y
p
e
ri
o
d
S
tu
d
y
p
o
p
u
la
ti
o
n
G
e
n
o
ty
p
in
g
to
o
ls
R
e
s
is
ta
n
c
e
te
s
ti
n
g
R
e
fe
re
n
c
e
s
W
G
S
M
L
S
T
E
R
IC
-P
C
R
P
F
G
E
R
e
p
P
C
R
O
th
e
r*
P
M
Q
R
Q
R
D
R
E
ffl
u
x
p
u
m
p
u
p
-
re
g
u
la
ti
o
n
a
a
c
(6
′
)-
Ib
-c
r
S
e
n
e
g
a
l
C
.
c
o
li
1
4
/3
6
B
,
M
2
0
0
0
–
2
0
0
2
C
h
ic
k
e
n
–
√
–
–
–
–
–
√
–
–
K
in
a
n
a
e
t
a
l.,
2
0
0
7
S
a
lm
o
n
e
lla
(N
T
S
)
S
.
Ty
p
h
i
4
/1
6
2
3
B
,
S
,
M
1
9
9
9
–
2
0
0
9
C
lin
ic
a
li
so
la
te
s
–
–
–
–
–
–
√
√
–
–
H
a
rr
o
is
e
t
a
l.,
2
0
1
4
C
.
je
ju
n
i
1
9
/4
6
B
,
M
2
0
0
0
–
2
0
0
2
C
h
ic
k
e
n
–
√
–
–
–
–
–
√
–
–
K
in
a
n
a
e
t
a
l.,
2
0
0
6
C
.
je
ju
n
i,
C
.
c
o
li
8
1
/1
8
1
B
,
M
2
0
0
0
–
2
0
0
3
P
o
u
ltr
y,
H
u
m
a
n
–
–
–
√
–
–
–
√
–
–
C
a
rd
in
a
le
e
t
a
l.,
2
0
0
6
S
ie
rr
a
L
e
o
n
e
V
.
c
h
o
le
ra
e
O
1
0
/1
5
B
,
M
,
S
2
0
1
2
C
lin
ic
a
li
so
la
te
s
–
–
–
√
–
–
–
–
–
–
M
a
h
m
u
d
e
t
a
l.,
2
0
1
4
S
o
u
th
A
fr
ic
a
E
.
c
o
li
1
4
/2
1
B
,
M
2
0
1
2
–
2
0
1
3
C
lin
ic
a
li
so
la
te
s
–
√
–
√
–
–
√
–
–
√
G
q
u
n
ta
a
n
d
G
o
ve
n
d
e
r,
2
0
1
5
S
.
Ty
p
h
i
1
/1
B
,
S
2
0
1
0
C
lin
ic
a
li
so
la
te
–
–
–
√
–
–
√
√
–
–
K
e
d
d
y
e
t
a
l.,
2
0
1
0
S
.
Ty
p
h
i
0
/5
1
0
B
,
S
2
0
0
3
–
2
0
0
7
C
lin
ic
a
li
so
la
te
s
–
–
–
√
–
M
LV
A
√
√
–
–
S
m
ith
e
t
a
l.,
2
0
1
0
S
.
Ty
p
h
i
N
S
/4
1
N
S
2
0
0
4
–
2
0
1
2
C
lin
ic
a
li
so
la
te
s
√
–
–
–
–
–
–
–
–
–
W
o
n
g
e
t
a
l.,
2
0
1
5
S
.
K
e
n
tu
c
k
y
1
/1
B
,
S
2
0
0
0
–
2
0
0
5
C
lin
ic
a
lI
so
la
te
s
–
–
–
√
–
–
√
√
–
–
W
e
ill
e
t
a
l.,
2
0
0
6
V
.
c
h
o
le
ra
e
O
1
O
g
a
w
a
E
l-
to
r
0
/3
1
B
,
S
,
M
2
0
0
8
O
u
tb
re
a
k
–
–
–
√
–
–
–
–
–
Is
m
a
il
e
t
a
l.,
2
0
1
1
Ta
n
za
n
ia
S
.
Ty
p
h
i
N
S
/5
2
N
S
2
0
0
6
–
2
0
1
0
C
lin
ic
a
li
so
la
te
s
√
–
–
–
–
–
–
–
–
–
W
o
n
g
e
t
a
l.,
2
0
1
5
S
.
K
e
n
tu
c
k
y
3
/3
B
,
S
2
0
0
0
–
2
0
0
5
C
lin
ic
a
lI
so
la
te
s
–
–
–
√
–
√
√
–
–
W
e
ill
e
t
a
l.,
2
0
0
6
K
E
Y
:
ID
m
e
th
o
d
:
B
,
B
io
c
h
e
m
is
tr
y;
S
,
S
e
ro
ty
p
in
g
;
M
,
d
e
te
c
ti
o
n
o
f
ta
rg
e
t
g
e
n
e
s
;
B
C
,
B
lo
o
d
c
u
lt
u
re
;
√
,
te
s
t
w
a
s
c
o
n
d
u
c
te
d
;
–
,
te
s
t
n
o
t
c
o
n
d
u
c
te
d
;
N
S
,
N
o
t
s
ta
te
d
(d
a
ta
n
o
t
in
c
lu
d
e
d
in
m
a
n
u
s
c
ri
p
t)
.
*O
th
e
r,
w
h
e
re
s
p
e
c
ifi
c
g
e
n
o
ty
p
ic
m
e
th
o
d
s
a
re
u
s
e
d
to
id
e
n
ti
fy
c
lo
n
e
s
o
f
th
a
t
e
n
te
ri
c
p
a
th
o
g
e
n
.
**
In
s
o
m
e
c
a
s
e
s
w
h
e
re
flu
o
ro
q
u
in
o
lo
n
e
-r
e
s
is
ta
n
t
c
lo
n
e
s
w
e
re
s
o
u
g
h
t
b
u
t
o
n
ly
q
u
in
o
lo
n
e
re
s
is
ta
n
t
o
r
n
o
n
-s
u
s
c
e
p
ti
b
le
is
o
la
te
s
w
e
re
id
e
n
ti
fie
d
.
D
e
ta
ils
o
f
th
e
s
e
s
tu
d
ie
s
a
re
p
ro
vi
d
e
d
in
Ta
b
le
S
2
.
W
G
S
,
W
h
o
le
g
e
n
o
m
e
s
e
q
u
e
n
c
in
g
;
M
L
S
T,
M
u
lt
i-
lo
c
u
s
s
e
q
u
e
n
c
e
ty
p
in
g
;
M
L
S
A
,
M
u
lt
i-
lo
c
u
s
s
e
q
u
e
n
c
in
g
a
n
a
ly
s
is
;
M
LV
A
,
m
u
lt
i-
lo
c
u
s
va
ri
a
b
le
-n
u
m
b
e
r
ta
n
d
e
m
re
p
e
a
t
a
n
a
ly
s
e
s
;
P
F
G
E
,
p
u
ls
e
fie
ld
g
e
l
e
le
c
tr
o
p
h
o
re
s
is
;
E
R
IC
-P
C
R
,
E
n
te
ro
b
a
c
te
ri
a
lR
e
p
e
ti
ti
ve
In
te
rg
e
n
ic
C
o
n
s
e
n
s
u
s
–
P
C
R
;
R
E
P
-P
C
R
,
re
p
e
ti
ti
ve
e
le
m
e
n
t
p
a
lin
d
ro
m
ic
P
C
R
;
R
F
L
P,
re
s
tr
ic
ti
o
n
fr
a
g
m
e
n
t
le
n
g
th
p
o
ly
m
o
rp
h
is
m
;
N
T
S
,
N
o
n
ty
p
h
o
id
a
lS
a
lm
o
n
e
lla
,
C
lin
ic
a
lI
s
o
la
te
s
–
fr
o
m
h
u
m
a
n
s
;
P
M
Q
R
,
p
la
s
m
id
m
e
d
ia
te
d
q
u
in
o
lo
n
e
re
s
is
ta
n
c
e
(in
c
lu
d
in
g
q
n
rA
,
q
n
rB
,
q
n
rS
,
q
n
rC
,
q
e
p
A
,
a
n
d
q
n
rV
C
3
);
Q
R
D
R
,
q
u
in
o
lo
n
e
re
s
is
ta
n
c
e
-d
e
te
rm
in
in
g
re
g
io
n
[in
c
lu
d
in
g
s
e
q
u
e
n
c
in
g
th
e
Q
R
D
R
o
f
D
N
A
g
yr
a
s
e
(g
yr
A
,
g
ry
B
)
a
n
d
to
p
o
is
o
m
e
ra
s
e
IV
(p
a
rC
,
p
a
rE
)
g
e
n
e
s
];
e
ffl
u
x,
e
ffl
u
x
u
p
re
g
u
la
ti
o
n
te
s
ti
n
g
;
a
a
c
(6
′ )-
Ib
-c
r,
a
m
in
o
g
ly
c
o
s
id
e
a
c
e
ty
lt
ra
n
s
fe
ra
c
e
a
s
s
o
c
ia
te
d
w
it
h
c
ip
ro
flo
xa
c
in
re
s
is
ta
n
c
e
;
D
R
C
,
D
e
m
o
c
ra
ti
c
R
e
p
u
b
lic
o
f
th
e
C
o
n
g
o
.
Frontiers in Microbiology | www.frontiersin.org 8 April 2016 | Volume 7 | Article 558
Chattaway et al. Fluoroquinolone-Resistant Enterics in Africa
(Kotloff et al., 2013). While there was a report of a single
quinolone-resistant Shigella isolate from Zaire in 1985 (Frost
et al., 1985) and Shigella epidemics caused by quinolone resistant
bacteria in the last century (Goma Epidemiology Group, 1995;
Karas and Pillay, 1996; Vlieghe et al., 2009) we did not identify
reports of fluoroquinolone-resistant clones of enteric E. coli
(FQREC) in the literature before 2000. Available reports appear
to suggest that most isolates were fluoroquinolone susceptible
until the end of the 1990s (Wistrom et al., 1987; Felmingham
and Robbins, 1992; Thornton et al., 1992; Bourgeois et al., 1993;
Oyofo et al., 1997; Decousser et al., 1999; Vila et al., 1999;
Ahmed et al., 2000; Okeke et al., 2000a,b; Jiang et al., 2002;
Orogade and Akuse, 2004). Our findings are corroborated by
other recent systematic reviews (Vlieghe et al., 2009; Leopold
et al., 2014).
Reports of fluoroquinolone-resistant E. coli from cases of
diarrhea and commensal reservoirs in Africa are limited to
the current millennium (Aibinu et al., 2004; Lamikanra et al.,
2011; Namboodiri et al., 2011; Fortini et al., 2015). One study
that examined human commensal isolates from Ghana (2006–
2008) found a wide range of STs associated with fluoroquinolone
resistance (Namboodiri et al., 2011). However, strains belonging
to the multilocus sequence type (ST) complex (specifically STs 10,
227, and 617) and the ST 156 sequence type complex (STs 156
and 1473) were detected 8 and 3 times respectively representing
half of the total number (22) of FQREC detected in the study.
An additional five ST10 isolates were resistant to nalidixic acid
and overall, ST10 strains were computed to be overrepresented
among quinolone-resistant E. coli (QREC) fromGhana (p= 0.02,
Fishers exact test; Namboodiri et al., 2011). Five ST10 QREC
(including four FQREC) harbored qnrS1, whilst other strains
carried qepA or qnrB2 genes. The ST156 strains harbored three or
more QRDRmutations, in contrast to most other strains that had
0–2 and one of the ST156 isolates also carried qepA. Interestingly,
multiple qepA-bearing FQREC ST156 strains have also been
reported as human commensals in the Central African Republic
and Nigeria (Table 2; Janatova et al., 2014; Fortini et al., 2015).
These and other lineages could be more broadly disseminated
but remain unflagged because data are insufficient or unavailable.
For example, qnrS1-bearing clones that have not been multilocus
sequence typed (clonality was inferred by ERIC-PCR) have also
been isolated from humans and pigs in Nigeria (Fortini et al.,
2011, 2015).
Invasive Escherichia coli
Fluoroquinolone-resistant E. coli are a rising cause of invasive
infections in Africa. The majority of reports of fluoroquinolone-
resistant enterobacterial lineages only seek lineage information
among ESBL-producers (Table 3; Aibinu et al., 2012a; Isendahl
et al., 2012; Breurec et al., 2013; Gqunta and Govender, 2015;
Rafai et al., 2015) so that the true prevalence of fluoroquinolone-
resistant strains is unknown as is the existence of ESBL-negative
fluoroquinolone-resistant lineages of importance. Interestingly,
while the data are few and biased toward ESBL-positive lineages,
there is some overlap between STs of FQREC recovered from
clinical infections and those found in the commensal reservoir
from humans and wild mammals (Tables 2, 3).
Kariuki et al. examined multiply resistant E. coli from urinary
tract infections in Kenya (Kariuki et al., 2007). Two PFGE profiles
were seen more than once. Strains belonging to these clones
had identical gyrA sequences, which included Ser83Leu and
Asp87Asnmutations in the QRDR regions of this gene. They also
carried a plasmid-borne aac-6(Ib)-cr gene and some had qnrA
and qnrB genes. Working largely with strains from other areas
but including 10 isolates from Bangui, Lavollay et al. found a
globally disseminated clone that carried an aac6-Ib-cr allele on
its CTX-M-15 bearing plasmid and detected two isolates of this
clone, as defined by REP-PCR and PFGE, among the Central
African Republic isolates (Lavollay et al., 2006).
Available data suggests that pandemic lineages circulate
within Africa. For example, fluoroquinolone-resistant strains
belonging to the globally disseminated E. coli ST131 lineage,
which is actually comprised of multiple clones, have rarely
been systematically sought but there are sporadic reports that
demonstrate their circulation in CAR (Rafai et al., 2015), Nigeria
(Aibinu et al., 2012a; Inwezerua et al., 2014), Guinea Bissau
(Isendahl et al., 2012), Tanzania (Lupindu et al., 2014), and South
Africa (Peirano et al., 2011, 2014; Gqunta and Govender, 2015;
Table 3). These data suggest that global dissemination may be
dictated by the pandemic potential of the ST131 lineages rather
than actual intercontinental transfer of specific clones.
Aibinu et al (Aibinu et al., 2012a) studied 109 E. coli isolates
obtained from two tertiary care hospitals in Lagos. Of the 14
isolates that were ESBL-producers, three were ST131 E. coli.
Chromosomal SNPs were not sought but two of the ST131
isolates and six other ESBL-producers (ST 10 complex—two
strains, STs 23, 295, 448, and 501) harbored the aac-(6′)-lb-
cr gene (Table 3). These eight strains and the pMQR-negative
ST131 strain all carried the ESBL-encoding CTX-M-15 gene. One
ST131 strain additionally carried a qnrB1 gene and a ST 617
strain (ST10 complex) carried qnrA1. This study demonstrated
the presence of ST131, as well as other notorious E. coli clones.
Many of the STs reported by Aibinu et al. were also found 2005
in the Nigerian study of Lamikanra et al. (2011) (2009 isolates
from that study were not sequenced typed) as well as among
2011 isolates from Fortini et al. (2015). Feglo et al. conducted
MLST on a subset of E. coli isolates from Kumasi Ghana,
hypothesizing that they would find ST131 strains among them.
Instead, they found that all of 29 isolates evaluated belonged
to the pyleonephritis-associated lineage ST88. Thus, regional
or internationally disseminated clones have been successful
in African settings and that locally successful clones are not
necessarily those with the greatest pandemic reputations.
Salmonella Typhi and Non-Typhoidal
Salmonella
Salmonella causes an estimated three billion infections in humans
and animals yearly (Crump et al., 2004; Coburn et al., 2007).
This poses significant socio-economic challenges, especially in
resource-limited settings. Classically, Salmonella can be divided
into two species, S. bongori and S. enterica (Crosa et al., 1973;
Schrire et al., 1987; Reeves et al., 1989). S. enterica can be further
divided into six sub-groups based on carbohydrate utilization,
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TABLE 2 | Multilocus sequence types of quinolone resistant commensals reported from potential reservoirs in sub-Saharan Africa.
City, Country Host organism Year Number of
independent
isolates
ST Quinolone resistance
mechanisms
References
Accra, Ghana Human 2006 2 E. coli (ST101) gyrA (S83L, D87N); qnrB1 Namboodiri et al., 2011
Accra, Ghana Human 2006 1 E. coli (ST617) gyrA (S83L, D87N); parC (S80I);
qnrS1
Namboodiri et al., 2011
Accra, Ghana Human 2006 2 E. coli (ST648) gyrA (S83L, D87N); parC (S80I) Namboodiri et al., 2011
Accra, Ghana Human 2006 1 E. coli (ST455) gyrA (S83L, D87N); parC (S80I,
N105S)
Namboodiri et al., 2011
Accra, Ghana Human 2006, 2007 2 E. coli (ST156) gyrA (S83L, D87N); parC (S80I,
E84K), qepA
Namboodiri et al., 2011
Accra, Ghana Human 2007 1 E. coli (ST1304) None detected Namboodiri et al., 2011
Accra, Ghana Human 2007 1 E. coli (ST450) gyrA (S83L, D87N) Namboodiri et al., 2011
Accra, Ghana Human 2007, 2008 5 E. coli (ST10) gyrA (S83L, D87N); parC (S80I),
qepA, qnrS1
Namboodiri et al., 2011
Accra, Ghana Human 2007 1 E. coli (ST354) gyrA (S83L, D87N); parC (S80I,
E84G), qnrB
Namboodiri et al., 2011
Accra, Ghana Human 2008 1 E. coli (ST1473) None detected Namboodiri et al., 2011
Accra, Ghana Human 2008 1 E. coli (ST1496) None detected Namboodiri et al., 2011
Accra, Ghana Human 2008 2 E. coli (ST227) gyrA (S83A), qnrS1 Namboodiri et al., 2011
Accra, Ghana Human 2008 1 E. coli (ST410) gyrA (S83L, D87N); parC (S80I) Namboodiri et al., 2011
Accra, Ghana Human 2008 1 E. coli (ST1468) gyrA (S83L, D87N); parC (S80I) Namboodiri et al., 2011
Accra, Ghana Human 2008 1 E. coli (ST131) gyrA (S83L, D87N); parC (S80I,
E84V)
Namboodiri et al., 2011
Accra, Ghana Human 2008 1 E. coli (ST1470) gyrA (S83L, D87N); parC (S80I,
A108V)
Namboodiri et al., 2011
Dzanga, CAR African buffalo 2011 1 K. pneumoniae (ST1208) oqxA Janatova et al., 2014
Dzanga, CAR African buffalo 2011 1 K. pneumoniae (ST1209) oqxA Janatova et al., 2014
Dzanga, CAR Peter’s Dunker 2011 1 K. pneumoniae (ST1210) oqxA Janatova et al., 2014
Dzanga, CAR Human 2011 4 E. coli (ST3476) qnrS1 Janatova et al., 2014
Dzanga, CAR Human 2011 3 E. coli (ST156) qepA Janatova et al., 2014
Dzanga, CAR Human 2011 1 E. coli (ST69) oqxA Janatova et al., 2014
Dzanga, CAR Human 2011 1 E. coli (ST218) qnrB1 Janatova et al., 2014
Dzanga, CAR Gorilla 2011 1 E. coli (ST424) qepA Janatova et al., 2014
Northern Kenya Dogs 2012 3 E. coli (ST131*) aac(6’)-Ib-cr Janatova et al., 2014
Ile-Ife, Nigeria Human 2005 9 E. coli (ST10 complex) gyrA (S83L), efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 2 E. coli (ST452) efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 2 E. coli (ST517) efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 1 E. coli (ST494) efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 1 E. coli (ST156) efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 1 E. coli (ST521) efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 1 E. coli (ST448) gyrA (S83L, D87N); parC (S80I),
efflux
Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 1 E. coli (ST503) efflux Lamikanra et al., 2011
Ile-Ife, Nigeria Human 2005 1 E. coli (ST504) gyrA (S83L), efflux Lamikanra et al., 2011
Ibadan, Nigeria Human 2011 1 E. coli (ST10) qnrS1, aac(6’)-Ib-cr Fortini et al., 2015
Ibadan, Nigeria Human 2011 1 E. coli (ST156) qepA1 Fortini et al., 2015
Ibadan, Nigeria Human 2011 1 E. coli (ST3147) qnrS1 Fortini et al., 2015
Senegal Poultry 2000–2002 11 C. jejuni (ST1036) gyrA (H81, S119, T86I, G110) Kinana et al., 2006
Senegal Poultry 2000–2002 3 C. jejuni (ST1040) gyrA (H81, S119, T86I) Kinana et al., 2006
Senegal Poultry 2000–2002 5 C. jejuni (ST1039) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 3 C. jejuni (ST1041) gyrA (H81, S119, T86A, G110) Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST1081) None detected Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST660) None detected Kinana et al., 2006
(Continued)
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TABLE 2 | Continued
City, Country Host organism Year Number of
independent
isolates
ST Quinolone resistance
mechanisms
References
Senegal Poultry 2000–2002 1 C. jejuni (ST22) None detected Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST1037) gyrA (H81, S119, T86I) Kinana et al., 2006
Senegal Poultry 2000–2002 3 C. jejuni (ST1038) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 4 C. jejuni (ST52) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST824) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST1359) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST1211) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST1370) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 1 C. jejuni (ST1358) gyrA (H81, S119) Kinana et al., 2006
Senegal Poultry 2000–2002 8 C. jejuni (ST1035) gyrA (H81, S119, G110, T86A,
T86I)
Kinana et al., 2006
*Determined by marker-based PCR not MLST.
TABLE 3 | Multilocus sequence types of fluoroquinolone-resistant E. coli clinical isolates reported from sub-Saharan Africa.
City, Country Isolation source Year Number of
independent
isolates
ST Reported quinolone
resistance
mechanisms
Other resistances References
Kumasi, Ghana Blood, Urine, sputum
and wounds
2008–2009 28 88 Whittam
scheme (Lacher
et al., 2007)
None reported ESBLs, gentamicin,
trimethoprim-
sulphamethoxazole,
chloramphenicol
Feglo et al., 2013
Bangui, CAR Surgical site infections 2011–2012 12 10 qnrB,qnrS,
aac(6’)-Ib-cr
ESBLs Rafai et al., 2015
Bangui, CAR Surgical site infections 2011–2012 1 146 qnrB, qnrS,
aac(6’)-Ib-cr
ESBLs Rafai et al., 2015
Bangui, CAR Surgical site infections 2011–2012 12 131 qnrB, qnrS,
aac(6’)-Ib-cr
ESBLs Rafai et al., 2015
Bangui, CAR Surgical site infections 2011–2012 5 156 qnrB, qnrS,
aac(6’)-Ib-cr
ESBLs Rafai et al., 2015
Bangui, CAR Surgical site infections 2011–2012 1 354 qnrS, aac(6’)-Ib-cr ESBLs Rafai et al., 2015
Bangui, CAR Surgical site infections 2011–2012 2 405 qnrB, aac(6’)-Ib-cr ESBLs Rafai et al., 2015
Cape Town,
South Africa
Urine and Pus 2008–2009 5 131* aac(6’)-Ib-cr ESBLs Peirano et al., 2011
Ibadan, Nigeria Urine 2010–2011 1 2695 qnrB, aac(6’)-Ib-cr ESBLs Inwezerua et al., 2014
Ibadan, Nigeria Vaginal 2010–2011 1 131 aac(6’)-Ib-cr ESBLs Inwezerua et al., 2014
Lagos, Nigeria Urine 2011 2 131 qnrB, aac(6’)-Ib-cr Aibinu et al., 2012b
Lagos, Nigeria Urine and stool 2011 2 617 (10
complex)
qnrB, aac(6’)-Ib-cr Aibinu et al., 2012b
Lagos, Nigeria Urine and stool 2011 1 295 aac(6’)-Ib-cr Aibinu et al., 2012b
Lagos, Nigeria Urine and stool 2011 1 23 aac(6’)-Ib-cr Aibinu et al., 2012b
Lagos, Nigeria Urine and stool 2011 1 448 aac(6’)-Ib-cr Aibinu et al., 2012b
Lagos, Nigeria Urine and stool 2011 1 501 aac(6’)-Ib-cr Aibinu et al., 2012b
Port Elizabeth,
South Africa
Clinical 2012–2013 12 131* qnrB qnrS,
aac(6’)-Ib-cr
ESBLs Gqunta and Govender,
2015
E. coli STs are defined by the Achtman scheme unless otherwise indicated (Wirth et al., 2006).
*Determined by marker-based PCR not MLST.
flagellar, and lipopolysaccharide (LPS) structures (Tindall et al.,
2005; Coburn et al., 2007; Grimont and Weill, 2007). Currently
there are more than, 2550 serovarieties of S. enterica. S. enterica
is responsible for most cases of salmonellosis in human and
warm-blooded animals (Brenner et al., 2000). Based on the type
of disease syndrome and host specificity, S. enterica can be
broadly divided into two groups (typhoidal and non-typhoidal).
“Typhoidal Salmonellae” are generally human-restricted and
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cause enteric fever; these include S. Typhi and S. Paratyphi. The
non-typhoidal salmonellae (NTS) encompass several serovars
with broad hosts including animals and humans such as
S. Typhimurium, S. Enteritidis, S. Poona, and S. Isangi. (Dougan
et al., 2011). In the WHO Africa sub-region, the burden of non-
typhoidal gastroenteritis is estimated at 2.5 million cases and
4100 deaths per year (Majowicz et al., 2010) but this estimate is
based on few data. Nontyphoidal Salmonella are also risk factors
for mortality from childhood diarrhea (O’Reilly et al., 2012). NTS
serovars are commonly associated with gastrointestinal disease
in hosts but can sometimes cause invasive or systemic disease in
humans and animals (Dougan et al., 2011; Langridge et al., 2012).
Emerging epidemiological data from across the subcontinent
shows that invasive non-typhoidal Salmonella (iNTS) infection
has become a major cause of bloodstream infections, overtaking
typhoidal enteric fever in many places, especially among malarial
and malnourished children and in HIV-positive adults (Reddy
et al., 2010). Mortality rates in these vulnerable populations
are reported to be as high as 30% in the absence of adequate
treatment (Berkley et al., 2005; Reddy et al., 2010). Multidrug
resistance of salmonellae to ampicillin, chloramphenicol and
trimethoprim-sulphamethoxazole (traditional regimens, cheap,
and orally active) is a global phenomenon, presenting particular
salmonellosis management challenges in Africa including the
epidemic of invasive S. Typhimurium ST 313. This clone consists
of two closely related lineages that emerged independently ∼
55 and ∼37 years ago, in close temporal association with the
HIV pandemic (Kingsley et al., 2009; Okoro et al., 2012). The
MDR genes of ST 313 are encoded on a Tn21-like element
borne on a virulence plasmid pSLT-BT. MDR clones of S. Typhi
have also emerged and spread intercontinentally and globally
involving Africa countries like Kenya (Kariuki et al., 2010; Holt
et al., 2011). Prevalence rates of MDR as high as 60.4, 80.7, and
94.7% have been reported from Kenya (Kariuki et al., 2010),
DRC (Lunguya et al., 2013), and Malawi (Feasey et al., 2010),
respectively. Increasing and dissemination of MDR clones of
salmonellae warranted the current use of fluoroquinolones and
third generation cephalosporins as the drugs of first choice for
treatment (Kariuki and Dougan, 2014; Kariuki et al., 2015a).
These newer drugs are expensive and pose significant challenges
to resource poor settings. The use of these drugs, together with
the use of over-the-counter and substandard antibiotics, has
now selected resistance to these drugs in salmonellae (Brenner
et al., 2000; Parkhill et al., 2001; McClelland et al., 2004;
Berkley et al., 2005; Gordon et al., 2008; Holt et al., 2008;
Kingsley et al., 2009; Majowicz et al., 2010; Reddy et al., 2010;
Dougan et al., 2011; Langridge et al., 2012; Okoro et al., 2012;
O’Reilly et al., 2012; Kariuki and Dougan, 2014; Kariuki et al.,
2015a) Initial reports of reduced susceptibility and resistance to
quinolones in NTS emerged in the mid 2000’s and continue to
trickle in from many sub-Saharan African countries including
Nigeria (Akinyemi et al., 2007), DRC (Lunguya et al., 2013),
Tanzania (associated with travel; Weill et al., 2006), Senegal
(Harrois et al., 2014), and Ghana (Nielsen et al., 2012). A
Mozambican study identified ∼5% of isolates as being resistant
to nalidixic acid; resistance to nalidixic acid is regarded as a
precursor for 2nd and 3rd generation fluoroquinolone resistance
(Mandomando et al., 2009). Recent reports have shown that
strains of MDR S. Typhimurium ST313 primarily associated
with bloodstream infections have acquired an additional incHI2
plasmid that confers additional resistance to many β-lactams
including ceftriaxone. These pathovariants have been identified
in Kenya (Kariuki et al., 2015b) and Malawi (Feasey et al., 2014).
Other reports have shown an association with the acquisition
of extended-spectrum β lactamases (ESBLs) and decreased
susceptibility to fluoroquinolones in Salmonellae, the latter
attributable to plasmid-borne qnr genes, although mechanism
underlying the significance of this association has not been fully
explored (Akinyemi et al., 2007, 2011; Harrois et al., 2014).
There are more than 20 million cases of human typhoid fever
resulting in as many as 200,000 fatalities worldwide each year
(Crump et al., 2004; Arjyal et al., 2011). Reports of outbreaks
of MDR Typhi and Paratyphi emerged in the early 1990’s in
endemic countries in Asia and associated with travel to these
regions in non-endemic (Parry et al., 2002; Arjyal et al., 2011).
MDR in these instances was characterized by resistance to
the first-line drugs of treatment at that time which included
chloramphenicol, ampicillin, and cotrimoxazole. Subsequently
as was in the case of NTS, fluoroquinolones were introduced
as the preferred drug of treatment for enteric fever (Arjyal
et al., 2011). Resistance to this drug inevitably emerged with
widespread use. Isolates with full resistance or reduced resistance
to nalidixic acid and second generation fluoroquinolones such as
ciprofloxacin and ofloxacin now dominate in Asia and emerging
as the dominant isolates associated with enteric fever in many
countries in Africa (Keddy et al., 2010; Kariuki et al., 2015a;
Wong et al., 2015).
The epidemiology of fluoroquinolone resistant clones in sub-
Saharan Africa is still an emerging story (Kariuki et al., 2004;
Feasey et al., 2015; Wong et al., 2015). A travel-associated case
of ciprofloxacin resistant S. Typhi was reported in South Africa
with PFGE pattern 100% identical to pattern JPPX01.0026 in the
Global PulseNet Salmonella Typhi (Keddy et al., 2010). However,
ciprofloxacin-resistant salmonellae appear uncommon in Africa,
at least within the available literature. Quinolone resistance and
decreased-susceptibility to fluoroquinolones (ciprofloxacin MIC
0.12–1.0µg/mL) are more prevalent (Table S2). Such strains
are of public health importance because there is correlation
between increasing MICs to fluoroquinolones and treatment
failure (Parry et al., 2011). The reported prevalence rates of
decreased susceptibility to ciprofloxacin from some African
countries are 0.3% (Senegal) (Harrois et al., 2014) 1.6% (Ghana)
(Nielsen et al., 2012), 4.3% (DRC) (Lunguya et al., 2013), and
∼5% (Mozambique) (Mandomando et al., 2009) with reports also
from Nigeria (Akinyemi et al., 2007) and Tanzania (Weill et al.,
2006), for NTS; and for S. Typhi: 5.3% (South Africa) (Smith
et al., 2010) and 60.4% (Kenya) (Kariuki et al., 2010). Some of
these prevalences are high enough to warrant shifting to other
antimicrobials but there are few alternatives in some of the least
aﬄuent African settings. There is an indication that different
clones of these strains could circulate in Africa (Smith et al., 2010)
and herald the emergence and dissemination of fluoroquinolone
resistance. With the exception of reports from specific countries
most notably Kenya (Kariuki et al., 2010) Malawi (Feasey et al.,
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2015), and South Africa (Keddy et al., 2010; Smith et al., 2010), a
systematic analyses of lineages associated with drug resistance is
yet to be reported. In the absence of a clearer picture, continued
first-line usage and misuse of quinolones is more than likely
to contribute the acquisition of drug resistance in typhoidal
Salmonellae.
Fluoroquinolone resistant salmonellae are more common in
animals compared to humans. A study in Senegal identified
Salmonella in almost all bovine carcasses screened. That study
reviewed earlier literature demonstrating that Salmonella in
animals and meat is commonplace in many African settings
(Stevens et al., 2006). Recently, the evolution and global
(including Africa) dissemination of fluoroquinolone resistant
S. Kentucky ST 198 X1-SGI 1 clone, which has poultry as the
main reservoir has occured (Le et al., 2013). This epidemic clone
is widespread in poultry in Nigeria and has persisted (Le et al.,
2013; Raufu et al., 2014). Using ciprofloxacin resistance as a
marker Le et al. (2013) reported that the strain is also probably
present in pigs in Nigeria, although the two isolates identified
in that study were not sequenced typed (Fashae and Hendriksen,
2014).
DISCUSSION
Assessing Clonality and Tracking
Expansion
Methods that have been used to identify fluoroquinolone-
resistant bacterial clones in Africa vary across the continent,
making between-study and cross-country comparisons difficult
(Quilici et al., 2010; Ismail et al., 2011; Marin et al., 2013). For
toxigenic V. cholerae for example, serotyping and biotyping—
both insufficient to confirm clonality—are only occasionally
performed outside clinical reference laboratories (Quilici et al.,
2010; Ismail et al., 2011). Genotyping the ctxB product (Quilici
et al., 2010), MLSA (Marin et al., 2013), and PFGE (Ismail et al.,
2011; Marin et al., 2013) have been used to infer clonality in
African studies. PFGE has been employed in multiple studies but
different protocols were used and the data are therefore non-
comparable. Moreover, PFGE identifies different clusters within
local clones and would not be a robust method for assessing
clonality across Africa (Ismail et al., 2011).
One reason why so many methods have been employed
is that so many methods abound. However the robustness,
replicability, and inferences that can be made from available
methods differ considerably. Methods based on phenotype or
PCR amplification patterns have been more widely used in the
decades following the evolution of fluoroquinolone resistance
but have limited replicability across laboratories and in some
cases, limited resolving power (Achtman, 1996). Serotyping is
very popular but has the additional downside of being dependent
on very labile reagents, a concern that is of particular importance
in African laboratories. To ascertain the relatedness of pathogenic
bacteria, methods that are specific enough to identify clusters
of related isolates and of high resolution to distinguish isolates
within these groups are ideal. Many classical molecular typing
methods are based on the sequences of a few small loci of
interest or on electrophoretic profiles dependent on particular
nucleotide patterns. These principles respectively form the basis
of multilocus sequence typing (MLST) and the comparison of
PFGE patterns. Assessing MLST types and PFGE patterns are the
methods most commonly used to infer clonality of sporadic or
epidemic cases of enteric diseases in sub-Saharan Africa. They
offer much greater reproducibility and portability than PCR-
based or phenotypic methods and while they were initially pricey,
set-up, and consumable costs have fallen dramatically in the
last two decades. The major disadvantages of these methods
are that they analyze a very small portion of the bacterial
genome and different parts of a genome accumulate variation at
different rates and/or are horizontally inherited. Finally, whilst
still utilizable in specific circumstances, these methods lack the
level of resolution needed to distinguish between very closely
related bacteria.
The arrival of the so-called next-generation, high-throughput
sequencing technologies makes it feasible to use WGS to identify
and track clones of interest. The major intrinsic challenges so
far have been high cost, inadequate infrastructure to maintain
sensitive equipment and lack of technical capacity. Overcoming
these surmountable challenges will present the opportunity to
use the best-fit methods for studying the epidemiology and
transmission of infectious diseases in such high burden areas in
sub-Saharan Africa. It is increasingly important to situate these
resources for WGS and analysis in areas with the most need to
maximize gains. In the interim, a transitional advantage of WGS
is that it can be used to generate comparative data for sequence
based methods with less resolution, such as MLST.
The power and utility of WGS tools is exemplified in a recent
study detailing the analyses of a global collection of S. Typhi
(Wong et al., 2015). The S. Typhi H58 haplotype MDR clone has
been shown to rapidly expand such as is the case in Malawi in
which prior to 2011, sporadic Typhoid was caused by a diversity
of clades. In their study, Wong et al. used a combination of WGS
and Bayesian analyses to deduce the global population structure,
possible intra- and inter-continental transmission pathways and
an estimate of time of emergence of the most recent common
ancestor of the current H58 global pandemic. These analyses
confirmed the highly clonal nature of the H58 isolates, which
were very similar to each other genetically (in fact, only∼6 SNPs
separates any two H58 strains). They were also able to detect
potential on-going epidemics in endemic countries. The H58
clones were estimated to have emerged in the late 1980’s and
are associated with high levels of drug resistance and reduced
susceptibility to fluoroquinolones, due to mutations in DNA
gyrase subunit and topoisomerase IV genes (Wirth, 2015; Wong
et al., 2015). This is consistent with epidemiological and clinical
data from the regions included in the study. This kind of analysis
allows identification of genomic changes and acquisitions that
underpin many observable phenotypes like increased infectivity,
transmissibility or fitness when compared to closely related
lineages of the same species. For example, Wong et al provide
evidence to show that a chromosomally borne MDR locus and
loss of an IncHI1 plasmid in a vast number of examined isolates
may have increased the fitness of the H58 clones (Wirth, 2015;
Wong et al., 2015).
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Exacerbating Factors, Intervention and
Research Needs
Clonal expansion of fluoroquinolone resistance in enterics is
broadly the consequence of antimicrobial pressure and bacterial
and gene dissemination. Antimicrobial resistance is a “Tragedy
of the Commons” evolutionary paradigm that is worsened by
failure to appreciate the problem; that is the absence of a
“recognition of necessity” (Hardin, 1968; Okeke, 2009). Thus,
infrastructural, bacterial and human-related factors exacerbate
the effects of antimicrobial pressure and bacterial exchange. Sub-
par diagnostic infrastructure leads to incorrect estimation of
true disease burden and veiling of significant resistant clones.
The lack of national, regional and internationally coordinated
antimicrobial stewardship leads to inconsistencies and non-
uniformity in many reported cases; this makes it difficult to
interpret data and to select truly representative studies.
Antimicrobial Pressure
Antimicrobial pressure plays a large, important and potentially
controllable role in the expansion of clonal resistance. Vien
et al. showed that the prevalence of qnr resistance genes in gut
Proteobacteria can increase following one course of antibiotic
treatment (Vien le et al., 2012). In African countries, the
contribution of pressure has not been measured, as antimicrobial
use in humans and animals remains largely undocumented.
Nonetheless, a high infectious disease burden warranting
justifiable antimicrobial use, poor diagnostic test infrastructure
and uptake and unregulated use of antibiotics combine to
exacerbate the adverse effects that antimicrobial use has on
resistance, and it’s potential to select undesirable clones. While
the community impact of antimicrobial use and overuse are
often discussed, (Feasey et al., 2014) recently presented a case
study illustrating that antimicrobial use can be associated with
acquisition of fluoroquinolone resistance by a highly virulent
clone of Salmonella Typhimurium in a treated patient. In that
case study, recrudescence of a bloodstream infection isolate
after acquisition of a resistance plasmid is the most likely
explanation for death. The effects of antimicrobial pressure
on the evolution of fluoroquinolone resistance extend beyond
quinolone use. Evidence suggests that fluoroquinolone-resistant
clones are selected and maintained by multiple antimicrobial
classes, a feature that is easily explained by the fact that
the successful clones in question are resistant to multiple
antimicrobials. Interventions are required to prevent the over-
prescription of antibiotics and preventing unsanctioned use in
humans and livestock. Policies that address these issues have long
been in existence but are inadequately implemented inmost parts
of Africa (WHO, 2001).
Antibiotic use strategies such as mixing and cycling have
been a proposed tool for reducing antibiotic resistance. Such
proposals are based on very few investigations, which give
variable results as to their effectiveness (Brown and Nathwani,
2005; Abel zur et al., 2014). Studies with S. Typhi have shown
that FQ resistance is not typically associated with fitness cost and
suggests that FQ resistant strains would be naturally maintained
even if fluoroquinolones use was reduced and so antibiotic
cycling is unlikely to be beneficial (Baker et al., 2013). Even
if mixing or cycling might be effective under some conditions,
Africa currently has too few effective antimicrobial classes to
effectively employ such techniques. In particular, withdrawing
fluoroquinolones out of rotation limits treatment options for
multiple life-threatening infections.
Dissemination
Enteric infections are principally attributable to poor sanitation,
hygiene, food safety and access to potable water. Lack of
such basic infrastructure contributes to endemicity in resource-
poor settings and amplifies the prevalence of resistant strains
in humans as well as animal and environmental reservoirs.
Opportunities for bacteria to move from one colonized
individual to another enhance the dissemination of resistant
clones. In Africa, crowded cities and significant numbers of
immunocompromised people are potential factors that could
enhance the dissemination of clones. Interestingly, mathematical
modeling to evaluate the impact of these risk factors found that
increased pathogen transmission rates and longer durations of
infectivity were even more important factors enabling spread,
(Pitzer et al., 2015). Therefore, whilst unjustified antimicrobial
use contributes to resistance, inadequate access to appropriate
antibiotics when needed could also exacerbate the problem.
Travel has been associated with the dissemination of
fluoroquinolone-resistant enteric clones in other parts of the
world (Soraas et al., 2013). While there are reports pointing to
export of resistant clones from African countries (Soraas et al.,
2013), research does not appear to have determined whether
and to what extent, resistant clones are imported into Africa.
Research by Okoro et al. points to inter-country dissemination of
multiply resistant non-typhoidal Salmonella in Africa but there
are also very few studies documenting regional transmission as
well (Okoro et al., 2012).
Clonal expansion of bacteria is often associated with selective
advantage conferred by changes in bacterial genomes. These
changes can be in the form the acquisition of chromosomal
and/or plasmid-borne MDR determinants as well as mutations
in genes targeted by antimicrobials, subsequently leading to
the emergence and maintenance of fitter clones in animals
and humans. This systematic review has shown that pandemic
lineages within Africa are sometimes represented by different
within-lineage clones than those elsewhere, pointing to bacterial
factors that promote clonal expansion in select lineages.
Host factors including presence of underlying conditions such
immunosuppression (Gordon et al., 2007; MacLennan et al.,
2008) and human migratory patterns attributable to social
and economic pressures also contribute to the emergence and
maintenance of MDR clones in Africa.
Surveillance
Our literature review identified very little research on
fluoroquinolone-resistant enteric clones within Africa. There are
however a large number of reports of fluoroquinolone resistant
clones isolated in Europe and North America (Pitout et al., 2009;
Soraas et al., 2013)that associate clone acquisition with travel
to African countries (for example Pitout et al., 2009; Soraas
et al., 2013). These “eyes of the hippopotamus” (Guerrant et al.,
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2005) reports point to under-detection and under reporting in
Africa and the need for more local studies to estimate the true
magnitude and extent of the problem. Our research also did
not uncover significant information about resistance reservoirs,
particularly in non-human hosts and the environment. What
few animal data we did encounter however points to a large
non-human reservoir of enteric organisms, many of them
resistant, and the occurrence of these organism through the
food chain. Studies reviewed for this paper were almost entirely
small research studies on human isolates from a handful of
laboratories. The location of these laboratories is the principal
determinant of locations on the continent from which data
are available. In order to understand resistance and track the
emergence of clones, multi-center surveillance is required.
The European Antimicrobial Resistance Surveillance
Network (EARS-Net) enables comparison between European
countries (http://ecdc.europa.eu/en/activities/surveillance/
EARS-Net/Pages/index.aspx). Recent analysis of the data has
shown that an increase of fluoroquinolone consumption in
Europe also increases the rate of resistance (Redgrave et al.,
2014). To understand the scale of resistance in Africa, a similar
model based on a regulated and coordinated surveillance system
across Africa would be ideal. In contrast to the EU, where an
obvious framework for coordination exists, it is less clear how to
implement such a scheme across Africa. Potential frameworks
include public as well as private sub-regional alliances and
there are multicountry data from the Francophone Pasteur
Institute Network (Breurec et al., 2013). Continental coverage
cannot be obtained from either. Looking forward, a regional
organization, perhaps the nascent African Society for Laboratory
Medicine, or perhaps a purpose-initiated one, might be lead
such an initiative. Alternatively, different laboratories and
networks could feed data to a repository. As well as putting
in proposed minimum reporting guidelines for research on
antimicrobial resistance (Omulo et al., 2015), the surveillance
system would also be expanded to include detection of clones
and mechanisms of resistance that are causing resistance so that
the spread can be tracked in real-time. A defined methodology
for assessing clones to enable tracking would be needed so that
different strains across Africa could be accurately compared
and experience from Europe suggests that this is best achieved
through sequence-based methods.
A network is only as good as the data it can collate from
participating countries. Implementation of such a scheme in
some countries would be difficult, given the state of existing
infrastructure but existing institutions in many other countries
that may be well-positioned to provide a local picture of
resistance problems if the necessary coordination were to occur.
As has been recently reported from Ghana, it is possible to set
up a national surveillance system coordinated from the ministry
of health (Opintan et al., 2015). The laudable Ghanaian initiative
was not without its challenges, many of them linked to resource
limitations, and the problem that most of the usable data came
from only a handful of participating institutions, mostly referral
hospitals. However inception is the first step in building a
robust surveillance system and most African countries are yet to
reach that point. In low-income African settings, it is predicted
that susceptibility data will save lives and costs, compared to
widespread used empirical therapy without local susceptibility
information (Penno et al., 2015).
In addition to microbiological infrastructure and activity,
support is needed for molecular studies that will identify the
underlying genetic bases for resistance, including the existence
and transmission of resistant clones. Comparison of isolates from
within sub-Sahara Africa to those from outside the sub-region
is important as recent studies have shown that clinical, cultural
practices and socio-economic factors impact on the nature of
circulating MDR clones in different parts of the world. Better
antibiotic stewardship at local, country, and regional levels is
needed in order to monitor and standardize protocols used for
testing and clinical prescription. Much of the inquiry around
antimicrobial resistance in African countries occurs within
academic and non-governmental sectors, a likely contributor to
fragmentation and limited coverage. Government participation
and lead in public health initiatives such as strengthening of
existing infrastructure and development of medical and research
capacity remain a critical need.
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